glp-1 drug makers Medications for Weight Loss GLP-1 Medications | Daniel Stark
Description
Methods A systematic review was conducted following PRISMA 2020 guidelines (PROSPERO: CRD420261305875)
Tirzepatide), metabolic outcomes, and next-gen weight loss benefits
While GLP-1 RAs induce weight loss in diabetes, their metabolic impact in normoglycaemic PD patients appears limited
Policy and Global Health Policy advances in 2025 laid critical groundwork for the next phase of obesity care
